Jupiter Asset Management Ltd. Increases Holdings in Progyny, Inc. $PGNY

Jupiter Asset Management Ltd. lifted its position in Progyny, Inc. (NASDAQ:PGNY) by 24.3% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 620,216 shares of the company’s stock after purchasing an additional 121,233 shares during the period. Jupiter Asset Management Ltd.’s holdings in Progyny were worth $15,927,000 at the end of the most recent quarter.

Other large investors have also recently modified their holdings of the company. Geode Capital Management LLC lifted its holdings in Progyny by 1.1% during the fourth quarter. Geode Capital Management LLC now owns 1,972,219 shares of the company’s stock worth $50,655,000 after buying an additional 20,533 shares during the period. Jackson Creek Investment Advisors LLC purchased a new stake in Progyny during the fourth quarter worth $410,000. Royce & Associates LP lifted its holdings in Progyny by 45.8% during the fourth quarter. Royce & Associates LP now owns 55,259 shares of the company’s stock worth $1,419,000 after buying an additional 17,358 shares during the period. New Age Alpha Advisors LLC purchased a new stake in Progyny during the fourth quarter worth $94,000. Finally, Hantz Financial Services Inc. lifted its holdings in Progyny by 79.4% during the fourth quarter. Hantz Financial Services Inc. now owns 1,676 shares of the company’s stock worth $43,000 after buying an additional 742 shares during the period. Hedge funds and other institutional investors own 94.93% of the company’s stock.

Insider Buying and Selling

In other Progyny news, COO Melissa B. Cummings sold 9,578 shares of the stock in a transaction dated Tuesday, May 19th. The stock was sold at an average price of $25.00, for a total transaction of $239,450.00. Following the sale, the chief operating officer directly owned 73,371 shares of the company’s stock, valued at approximately $1,834,275. This trade represents a 11.55% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Mark S. Livingston sold 8,275 shares of the firm’s stock in a transaction dated Wednesday, May 20th. The shares were sold at an average price of $25.50, for a total value of $211,012.50. Following the sale, the chief financial officer owned 79,063 shares in the company, valued at $2,016,106.50. This trade represents a 9.47% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 30,808 shares of company stock valued at $717,422 over the last quarter. 9.90% of the stock is currently owned by company insiders.

Progyny Stock Performance

Shares of PGNY opened at $25.56 on Friday. The business’s 50-day moving average is $19.83 and its two-hundred day moving average is $22.25. The company has a market capitalization of $2.00 billion, a P/E ratio of 33.19, a P/E/G ratio of 1.37 and a beta of 0.91. Progyny, Inc. has a fifty-two week low of $16.10 and a fifty-two week high of $28.75.

Progyny (NASDAQ:PGNY) last announced its quarterly earnings results on Thursday, May 7th. The company reported $0.50 earnings per share for the quarter, topping the consensus estimate of $0.26 by $0.24. The company had revenue of $328.50 million for the quarter, compared to the consensus estimate of $326.47 million. Progyny had a return on equity of 13.34% and a net margin of 5.23%.The firm’s revenue for the quarter was down 26.4% compared to the same quarter last year. During the same period last year, the firm earned $0.17 EPS. Progyny has set its FY 2026 guidance at 1.980-2.09 EPS and its Q2 2026 guidance at 0.500-0.53 EPS. Analysts forecast that Progyny, Inc. will post 1.12 EPS for the current year.

Progyny announced that its board has approved a share buyback plan on Tuesday, May 26th that allows the company to buyback $200.00 million in outstanding shares. This buyback authorization allows the company to purchase up to 10.3% of its stock through open market purchases. Stock buyback plans are often a sign that the company’s leadership believes its shares are undervalued.

Analysts Set New Price Targets

PGNY has been the subject of a number of analyst reports. BTIG Research lowered their target price on Progyny from $35.00 to $30.00 and set a “buy” rating for the company in a report on Thursday, March 5th. Citizens Jmp increased their price objective on Progyny from $30.00 to $31.00 and gave the company a “market outperform” rating in a report on Monday, May 11th. Truist Financial increased their price objective on Progyny from $28.00 to $30.00 and gave the company a “buy” rating in a report on Monday, May 11th. Barclays increased their price objective on Progyny from $23.00 to $27.00 and gave the company an “overweight” rating in a report on Friday, May 15th. Finally, Canaccord Genuity Group upgraded Progyny from a “hold” rating to a “buy” rating and increased their price objective for the company from $19.00 to $30.00 in a report on Tuesday, May 19th. One equities research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $29.55.

Progyny Profile

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.